Home » Stocks » ASLN

ASLAN Pharmaceuticals Limited (ASLN)

Stock Price: $2.93 USD -0.05 (-1.68%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $2.90 -0.03 (-1.02%) May 7, 7:00 PM
Market Cap 203.70M
Revenue (ttm) 189,710
Net Income (ttm) -16.97M
Shares Out 69.52M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $2.93
Previous Close $2.98
Change ($) -0.05
Change (%) -1.68%
Day's Open 2.82
Day's Range 2.81 - 3.00
Day's Volume 318,588
52-Week Range 1.26 - 6.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- ASLAN will give a poster presentation of new data from its Single Ascending Dose (SAD) study of ASLAN004, during the virtual event on 6 May, 2021

4 days ago - GlobeNewsWire

Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021 Next data readout for ASLAN004 in the treatment of patients...

2 weeks ago - GlobeNewsWire

ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives ...

2 months ago - GlobeNewsWire

SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives ...

2 months ago - GlobeNewsWire

Investors in ASLN stock seem to like the company's initial clinical test results, as well as the company's overall market position. The post ASLN Stock: Why Aslan Pharmaceuticals Is Up 20% Today appeare...

2 months ago - InvestorPlace

Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) announces positive interim unblinded data from its ongoing Phase 1 study evaluating ASLAN004 to treat moderate to severe atopic dermatitis (AD). Subcutaneous del...

2 months ago - Benzinga

- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90

2 months ago - GlobeNewsWire

SINGAPORE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of...

2 months ago - GlobeNewsWire

SINGAPORE, Feb. 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of...

2 months ago - GlobeNewsWire

— New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors

3 months ago - GlobeNewsWire

- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels

3 months ago - GlobeNewsWire

ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 months ago - Zacks Investment Research

SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of...

5 months ago - GlobeNewsWire

ASLAN Pharmaceuticals (ASLN) has been struggling lately, but the selling pressure may be coming to an end soon.

5 months ago - Zacks Investment Research

SINGAPORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of...

6 months ago - GlobeNewsWire

--   ASLAN has initiated recruitment of patients into third dos e cohort at sites in the US, Australia and Singapore following successful safety review of second cohort

6 months ago - GlobeNewsWire

ASLAN Pharmaceuticals (ASLN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million.

Other stocks mentioned: LGND, LLY, PPD
6 months ago - Seeking Alpha

--  ASLAN believe s ASLAN003 has the potential to be the most potent oral inhibitor of DHODH currently in development for autoimmune disease , more than 30 times more potent at inhibiting the DHODH enzy...

6 months ago - GlobeNewsWire

SINGAPORE, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transf...

7 months ago - GlobeNewsWire

SINGAPORE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transf...

7 months ago - GlobeNewsWire

Interim, unblinded data from all 3 dose cohorts in MAD study expected in 4Q 2020 Interim, unblinded data from all 3 dose cohorts in MAD study expected in 4Q 2020

8 months ago - GlobeNewsWire

SINGAPORE, Aug. 07, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments...

9 months ago - GlobeNewsWire

SINGAPORE, Aug. 03, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatment...

9 months ago - GlobeNewsWire

SINGAPORE, July 17, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatment...

9 months ago - GlobeNewsWire

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

9 months ago - Zacks Investment Research

SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments...

9 months ago - GlobeNewsWire

ASLAN Pharmaceuticals (ASLN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

ASLAN Pharmaceuticals Ltd. (ASLN) closed at $1.92 in the latest trading session, marking a +0.26% move from the prior day.

10 months ago - Zacks Investment Research

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

10 months ago - Zacks Investment Research

In the latest trading session, ASLAN Pharmaceuticals Ltd (ASLN) closed at $1.65, marking a +0.61% move from the previous day.

1 year ago - Zacks Investment Research

ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment

1 year ago - GlobeNewsWire

ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment

1 year ago - GlobeNewsWire

ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

SINGAPORE, March 18, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatment...

1 year ago - GlobeNewsWire

ASLAN Pharmaceuticals Ltd. (ASLN) closed the most recent trading day at $2.10, moving -1.87% from the previous trading session.

1 year ago - Zacks Investment Research

ASLAN Pharmaceuticals Ltd. (ASLN) closed at $2.11 in the latest trading session, marking a -0.94% move from the prior day.

1 year ago - Zacks Investment Research

ASLAN Pharmaceuticals Ltd. (ASLN) closed the most recent trading day at $2.17, moving +0.93% from the previous trading session.

1 year ago - Zacks Investment Research

Is (ASLN) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Is (ASLN) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in ASLAN Pharmaceuticals.

1 year ago - Zacks Investment Research

SINGAPORE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the closing of ...

1 year ago - GlobeNewsWire

The U.S.-listed shares of Aslan Pharmaceuticals Ltd. plunged 47% in active afternoon trading on Tuesday, after the Singapore-based biotechnology company's stock offering priced at less than half the pr...

1 year ago - Market Watch

Aslan Pharmaceuticals Ltd. (NASDAQ: ASLN) has been on a roller coaster for the past two weeks.

1 year ago - 24/7 Wall Street

SINGAPORE, Dec. 03, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has pri...

1 year ago - GlobeNewsWire

Shares of Aslan Pharmaceuticals Ltd. jumped 42% on heavy volume in afternoon trading, but pared by more than half earlier gains of over 100%, after the biotechnology company took advantage of a more-th...

1 year ago - Market Watch

SINGAPORE, Dec. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has commenced ...

1 year ago - GlobeNewsWire

After soaring 81.25% Wednesday and augmenting the gains by an incremental 65% Friday, ASLAN PHARMACEU/ADR (NASDAQ: ASLN) shares were  accelerating further Monday morning.

1 year ago - Benzinga

About ASLN

ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Industry
Biotechnology
IPO Date
May 4, 2018
CEO
Carl Firth
Employees
18
Stock Exchange
NASDAQ
Ticker Symbol
ASLN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ASLN stock is "Buy." The 12-month stock price forecast is 8.50, which is an increase of 190.10% from the latest price.

Price Target
$8.50
(190.10% upside)
Analyst Consensus: Buy